🇺🇸 INCLACUMAB in United States

6 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 6

Most-reported reactions

1. Infusion Related Reaction — 2 reports (33.33%)
2. Drug Ineffective — 1 report (16.67%)
3. Low Density Lipoprotein Increased — 1 report (16.67%)
4. Product Dose Omission Issue — 1 report (16.67%)
5. Sickle Cell Anaemia With Crisis — 1 report (16.67%)

Source database →

Frequently asked questions

Is INCLACUMAB approved in United States?

INCLACUMAB does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for INCLACUMAB in United States?

Marketing authorisation holder not available in our data.